

For HPV-positive cancer care

Your Blood TTMV® Can Guide the Way to More Personalized Care

Monitoring TTMV Scores* with NavDx® will help your physician assess your response to treatment and detect if your cancer returns, even before symptoms appear. With a simple blood draw NavDx can detect whether HPV-positive cancer is present anywhere in your body, helping providers create the best care plan for you.

Talk with your provider about how routine NavDx testing can help monitor your HPV-positive cancer status.

Here are some questions you may want to discuss:	
◆	Am I a candidate for routine NavDx testing?
◆	How has my cancer responded to treatment?
◆	How can NavDx be used to monitor for residual disease?
◆	How can NavDx be used to monitor for recurrence of my cancer?
◆	What can a positive (or negative) TTMV Score tell about my cancer status?
◆	How can detecting cancer recurrence early, before symptoms reappear, improve my overall chances of survival?
◆	Who on my care team will be ordering the test?
◆	How often should I have a NavDx test?
◆	What are my options regarding where to get my blood drawn?

* Blood TTMV, or tumor tissue modified viral (TTMV)-HPV DNA, is a specific biomarker for HPV-positive cancers that is measured with the NavDx test.



Talk with your provider about convenient, routine testing with NavDx and stay informed of your true cancer status

Be assured of your true cancer status...

Routinely test with NavDx®

After treatment, **regular monitoring with NavDx can help detect cancer earlier** than can be found through imaging, biopsies, or physical symptoms. Across numerous studies, NavDx accurately predicted when cancer returned. Among post-treatment patients:

- ◆ **≥98% of people** whose TTMV Score remained negative had no cancer
- ◆ **≥95% of people** with one positive TTMV Score had cancer recurrence

Talk with your provider to determine your eligibility for NavDx and plan your testing schedule

Both clinical practice guidelines and CMS (Medicare) coverage policy for recurrence recommend ongoing surveillance monitoring at specified intervals.

After treatment (monitoring for cancer recurrence):

- ◆ **≥3 months - 2 years post treatment:** every 3 months
- ◆ **3-5 years post treatment:** every 6 months
- ◆ **6+ years post treatment:** 1 time per year

When and how often your blood TTMV Score is monitored with NavDx is up to you and your physician.

Discuss all your TTMV Scores with your physician to stay informed of your true cancer status

My NavDx Testing Plan:

1. My treatment end date: _____
2. My NavDx test should be scheduled on or around this date: _____
3. The NavDx testing interval that is recommended by my provider: _____



Speak with your provider and set up a NavDx testing schedule that's right for you!



Naveris Inc., 21 Hickory Drive, Suite 600, Waltham, MA 02451
naveris.com | contact@naveris.com
© 2024 Naveris Inc. | US Patent 11,168,373 | NavDx-0924-163

NavDx®
Optimizing HPV+ Cancer Care